MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, will participate in the Stifel 2025 Virtual Cardiometabolic Forum. The company's leadership, including CEO Kent Hawryluk and CMO Dr. Sam Azoulay, will engage in a fireside chat on September 30, 2025, from 10:00 AM to 10:25 AM ET.
The virtual presentation will be accessible through a live webcast on the company's investor relations website, with a replay available for approximately 90 days following the event.
MBX Biosciences (Nasdaq: MBX), un’azienda biofarmaceutica in fase clinica specializzata in terapie peptidiche di precisione per disturbi endocrini e metabolici, parteciperà al Stifel 2025 Virtual Cardiometabolic Forum. Il management dell’azienda, tra cui il CEO Kent Hawryluk e il CMO Dr. Sam Azoulay, parteciperà a una chiacchierata informale il 30 settembre 2025, dalle 10:00 alle 10:25 ET.
La presentazione virtuale sarà disponibile tramite una webcast in diretta sul sito di relazioni con gli investitori dell’azienda, con un replay disponibile per circa 90 giorni dopo l’evento.
MBX Biosciences (Nasdaq: MBX), una empresa biofarmacéutica en etapa clínica especializada en terapias peptídicas de precisión para trastornos endocrinos y metabólicos, participará en el Stifel 2025 Virtual Cardiometabolic Forum. El equipo directivo, incluido el CEO Kent Hawryluk y el CMO Dr. Sam Azoulay, participarán en una charla informal el 30 de septiembre de 2025, de 10:00 a. m. a 10:25 a. m. ET.
La presentación virtual estará disponible a través de una transmisión en vivo en el sitio web de relaciones con inversores de la empresa, y habrá una reproducción disponible aproximadamente durante 90 días después del evento.
MBX Biosciences (나스닥: MBX), 내분비 및 대사 질환을 위한 정밀 펩타이드 치료제를 전문으로 하는 임상 단계의 생물의약 회사로서 Stifel 2025 Virtual Cardiometabolic Forum에 참여합니다. CEO Kent Hawryluk 및 CMO Dr. Sam Azoulay를 포함한 회사 경영진은 2025년 9월 30일 동부시간 ET 기준 10:00~10:25에 화롯대 대화를 진행합니다.
가상 발표는 회사의 투자자 관계 웹사이트에서 라이브 webcast로 접속할 수 있으며, 이벤트 종료 후 대략 90일 동안 재시청이 가능합니다.
MBX Biosciences (Nasdaq: MBX), société biopharmaceutique en phase clinique spécialisée dans les thérapies peptidiques de précision pour les troubles endocriniens et métaboliques, participera au Stifel 2025 Virtual Cardiometabolic Forum. L’équipe dirigeante, notamment le PDG Kent Hawryluk et le CMO Dr. Sam Azoulay, mènera une discussion informelle le 30 septembre 2025, de 10 h à 10 h 25 ET.
La présentation virtuelle sera accessible via une diffusion en direct sur le site Web des relations avec les investisseurs de l’entreprise, et un replay sera disponible pendant environ 90 jours après l’événement.
MBX Biosciences (Nasdaq: MBX), ein klinisch fortgeschrittenes Biopharmaunternehmen, das sich auf präzise Peptidtherapien für endokrine und metabolische Erkrankungen spezialisiert hat, wird am Stifel 2025 Virtual Cardiometabolic Forum teilnehmen. Die Geschäftsführung, darunter CEO Kent Hawryluk und CMO Dr. Sam Azoulay, wird an einem Fireside Chat am 30. September 2025, von 10:00 bis 10:25 Uhr ET teilnehmen.
Die virtuelle Präsentation wird über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiedergabe für ca. 90 Tage nach der Veranstaltung.
MBX Biosciences (ناسداك: MBX)، شركة أدوية حيوية في المرحلة السريرية ومتخصصة في علاجات ببتيدية دقيقة للاضطرابات الغددية والمت metabكية، ستشارك في منتدى Stifel الافتراضي للقلب الأيضي 2025. ستشارك قيادة الشركة، بما في ذلك المدير التنفيذي كيـنــــت هـاوريولك ومديرها الطبي الدكتور سام عزولاى، في دردشة أمام المدفئة يوم 30 سبتمبر 2025، من الساعة 10:00 إلى 10:25 صباحاً بتوقيت شرق الولايات المتحدة.
سيكون العرض الافتراضي متاحاً عبر بث مباشر على موقع علاقات المستثمرين بالشركة، وسيكون هناك إعادة تشغيل مدتها حوالي 90 يوماً بعد الحدث.
MBX Biosciences（纳斯达克：MBX），一家处于临床阶段的生物制药公司，专注于用于内分泌和代谢疾病的精准肽治疗，将参加 Stifel 2025 虚拟心代谢论坛。公司高层包括首席执行官 Kent Hawryluk 和首席医疗官 Dr. Sam Azoulay，将于 2025 年 9 月 30 日，东西方时间上午 10:00–10:25 进行炉边对话。
此次虚拟演示将通过公司投资者关系网站的现场直播提供，事件结束后大约 90 天内提供回放。
- None.
- None.
CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30.
Stifel 2025 Virtual Cardiometabolic Forum
Date: Tuesday, September 30, 2025
Format: Fireside chat
Time: 10:00 a.m. – 10:25 a.m. ET
Location: Virtual
The live webcast of the presentation can be accessed in the events sections of MBX’s website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; imapextide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When is MBX Biosciences presenting at the Stifel 2025 Virtual Cardiometabolic Forum?
Who will be representing MBX Biosciences at the Stifel 2025 Virtual Cardiometabolic Forum?
How can investors access MBX Biosciences' presentation at the Stifel Forum?
What is MBX Biosciences' primary focus as a company?
